Phaseline

Targets › MICU1

MICU1 (Calcium uptake protein 1, mitochondrial): drug programs, companies and trials

1 program from 1 company in 4 trials: 2 Phase 2, 2 Phase 1; Hematology, Oncology; next expected readout Dec 2026.

Calcium sensor of the mitochondrial calcium uniporter (MCU) channel, which senses calcium level via its EF-hand domains. MICU1 and MICU2 (or MICU3) form a disulfide-linked heterodimer that stimulates and inhibits MCU activity, depending on the concentration of calcium. (UniProt, Q9BPX6)

Open in Phaseline: the race on MICU1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
St. Jude Children's Research Hospital[13N]NH3
MICU1 inhibitor; mitochondrial calcium uniporter inhibitor
MICU1Phase 2Frailty; Sickle Cell Disease; Acute Pancreatitis; Acute Lymphoblastic Leukemia, in RelapseDec 2026

Conditions

Frailty (1) Sickle Cell Disease (1) Acute Pancreatitis (1) Acute Lymphoblastic Leukemia, in Relapse (1)

Modalities

small molecule (1)

Companies

St. Jude Children's Research Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.